<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331601</url>
  </required_header>
  <id_info>
    <org_study_id>UZBRU_VHH1_2</org_study_id>
    <secondary_id>2015-002328-24</secondary_id>
    <nct_id>NCT03331601</nct_id>
  </id_info>
  <brief_title>Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients</brief_title>
  <official_title>Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in
      brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative breast
      cancer will be included and the uptake in their lesions will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The tumor targeting potential in brain metastasis</measure>
    <time_frame>90 min post injection</time_frame>
    <description>The tumor targeting potential in brain metastasis and other known breast carcinoma lesions will be visually scored as positive or negative by an experienced nuclear medicine physician, unaware of the HER2-status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The tumor targeting potential in brain metastasis</measure>
    <time_frame>90 min post injection</time_frame>
    <description>The tumor targeting potential in brain metastasis and other known breast carcinoma lesions will be assessed quantitatively using Standard Uptake Values (SUV) by an experienced nuclear medicine physician, unaware of the HER2-status.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Neoplasm</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Receptor, ErbB-2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68GaNOTA-Anti-HER2 VHH1</intervention_name>
    <description>Injection of the radiopharmaceutical and PET/CT 90 min post injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given informed consent

          -  Female patients

          -  Age 18 years or older

          -  Patients with brain metastasized breast carcinoma, with at least 1 brain lesion of at
             least 8 mm maximal diameter, as measured by CT or MRI.

          -  20 patients with HER2-positive breast carcinoma and 10 with HER2-negative breast
             carcinoma will be included

        Exclusion Criteria:

          -  Male patients

          -  Pregnant patients

          -  Breast feeding patients

          -  Patients with recent (&lt; 1 week) gastrointestinal disorders with diarrhea as major
             symptom

          -  Patients with any serious active infection

          -  Patients who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the investigator would either compromise patient safety or
             interfere with the evaluation of the test radiopharmaceutical

          -  Patients who cannot communicate reliably with the investigator

          -  Patients who are unlikely to cooperate with the requirements of the study

          -  Patients who are unwilling and/or unable to give informed consent

          -  Patients at increased risk of death from a pre-existing concurrent illness

          -  Patients who participated already in this study, or in a previous trial with VHH1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen KEYAERTS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UZ Brussel</last_name>
    <phone>+3224776013</phone>
    <email>afspraak_nucleaire@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uz Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UZ BRUSSEL</last_name>
      <phone>+3224776013</phone>
      <email>afspraak_nucleaire@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Marleen Keyaerts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8.</citation>
    <PMID>26449837</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain metastasis</keyword>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

